Skip to content

ONYX PHARMACEUTICALS INC

CIK 0001012140

← back to feed
Revenue (TTM)
$460.73M
+42.9% YoY Q2 Aug 2013
Net Income (TTM)
−$175.49M
−346.7% YoY Q2 Aug 2013
EPS Diluted (TTM)
−$2.60
−356.0% YoY Q2 Aug 2013
Gross Margin
99.8%
Q2 Aug 2013
Operating Margin
-55.2%
Q2 Aug 2013
Net Margin
-38.1%
Q2 Aug 2013
Free Cash Flow (TTM)
$39.17M
Q2 Aug 2013
Cash
$323.07M
Q2 Aug 2013
Total Debt
—
Q2 Aug 2013
Shares Outstanding
73.34M sh
Q2 Aug 2013

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings